Pacira BioSciences (NASDAQ:PCRX) Rating Lowered to “Hold” at Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX) was downgraded by Needham & Company LLC from a “buy” rating to a “hold” rating in a report issued on Thursday, MarketBeat Ratings reports.

Other equities analysts have also issued reports about the company. Weiss Ratings lowered Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 26th. Royal Bank Of Canada boosted their price target on shares of Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Zacks Research cut shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research note on Monday. Finally, Leerink Partners assumed coverage on Pacira BioSciences in a report on Wednesday, September 9th. They set a “market perform” rating and a $28.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $31.44.

Pacira BioSciences Price Performance

NASDAQ PCRX opened at $36.39 on Thursday. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $36.46. The company has a fifty day simple moving average of $25.37 and a 200 day simple moving average of $24.51. The company has a market cap of $1.45 billion, a P/E ratio of 103.97 and a beta of 0.25.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The business had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. Pacira BioSciences’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.74 earnings per share. On average, sell-side analysts predict that Pacira BioSciences will post 1.91 EPS for the current year.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $23.23, for a total value of $70,619.20. Following the transaction, the insider directly owned 216,384 shares in the company, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pacira BioSciences

Several large investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its stake in shares of Pacira BioSciences by 8.6% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 43,764 shares of the company’s stock valued at $1,110,000 after purchasing an additional 3,482 shares during the period. Baird Financial Group Inc. acquired a new position in Pacira BioSciences during the second quarter valued at approximately $213,000. Amundi raised its holdings in Pacira BioSciences by 16.2% in the second quarter. Amundi now owns 15,894 shares of the company’s stock worth $403,000 after purchasing an additional 2,210 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at $851,000. Finally, Three Seasons Wealth LLC lifted its holdings in Pacira BioSciences by 43.6% during the second quarter. Three Seasons Wealth LLC now owns 62,942 shares of the company’s stock worth $1,597,000 after acquiring an additional 19,107 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Key Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris acquisition: Viatris will acquire Pacira’s marketed non-opioid pain products, including EXPAREL and ZILRETTA. The deal is expected to close by the end of 2026, subject to customary conditions, and Viatris expects it to be immediately accretive to its financial guidance metrics. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Analyst support: Pacira received an analyst upgrade, helping reinforce momentum following the takeover announcement. JPMorgan also raised its rating from “underweight” to “neutral” and set a $36.50 price target, broadly aligning with the proposed cash consideration. Pacira Stock Jumps on Analyst Upgrade
• Neutral Sentiment: Truist increased its price target to $31 while maintaining a “buy” rating, but the target is below the $36.50 acquisition price and is therefore less relevant if the deal closes. Jefferies and Needham reiterated “hold” ratings. Pacira Price Target Increase
• Negative Sentiment: Several shareholder law firms announced investigations into whether Pacira’s board obtained sufficient value for shareholders and conducted an adequate sale process. These reviews could create litigation or deal-execution risk, although no specific wrongdoing has been established. Shareholder Investigation

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.